May 012024
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Xolremdi | mavorixafor | 4/26/2024 | To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) | Drug Trials Snapshot | |
| Ojemda | tovorafenib | 4/23/2024 | To treat relapsed or refractory pediatric low-grade glioma | ||
| Anktiva | nogapendekin alfa inbakicept-pmln | 4/22/2024 | To treat bladder cancer | ||
| Lumisight | pegulicianine | 4/17/2024 | To use as an optical imaging agent for the detection of cancerous tissue | ||
| Zevtera | ceftobiprole medocaril sodium | 4/3/2024 | To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia | Press Release |
Sorry, the comment form is closed at this time.